Promoting Neuroprotection: Lessons Learned from Eae*

Experimental autoimmune encephalomyelitis (EAE) is the primary animal model used for studying multiple sclerosis (MS). Here we discuss 3 examples of molecular targets identified through studies of EAE and comment on their application in the treatment of MS. The anti-very late antigen 4 antibody, natalizumab, has shown marked therapeutic effects through the blockade of T-cell interactions with vascular endothelium of the blood-brain barrier. Insulinlike growth factor 1 stimulation of myelin production, in contrast, has had variable effects. Finally, inhibition of Nogo-A, neurite outgrowth inhibitor, shows promise as therapeutic means to combat axonal transection. Thus studies of EAE have provided insights into potential therapies targeting MS at many different levels. (Adv Stud Med. 2007;7(8):228-232) T he animal model for multiple sclerosis (MS) is experimental autoimmune encephalomyelitis (EAE). The clinical course of the disease mimics certain types of MS whereas histopathology shows marked resemblance to central nervous system (CNS) lesions seen in MS. Although the model has shortcomings, several key molecular observations have translated to MS. This article will review some of the molecular targets in the EAE model that have found or are finding their way to human clinical trials.